Apellis MSL (Medical Science Liaison)
Remote role based in NSW, focused on developing and maintaining peer‐to‐peer scientific relationships with key medical experts in NSW and QLD. This role primarily supports the Apellis ophthalmology program within the Medical Affairs department.
Summary
The role involves collaborating with ophthalmologists and other eye care professionals to support the medical strategy and ensure dissemination and discussion of up‐to‐date medical information based on scientific exchange.
Roles and Responsibilities
* Develop and maintain peer‐to‐peer collaborations and relationships with key medical experts in the ophthalmology community
* Support medical affairs (e.g., scientific exchange, conference support) and clinical development initiatives (e.g., site identification, trial recruitment)
* Collaborate with physicians on medical affairs initiatives including publications, advisory boards, medical education opportunities, and training
* Serve as scientific peer‐to‐peer resource to external disease experts and internal stakeholders
* Provide the medical community with up‐to‐date medical information, robust disease expertise, and product information
* Communicate clinical insights on new data to Apellis Medical Affairs and inform medical strategy for the therapeutic area
* Train internal stakeholders on key scientific and medical topics in the relevant therapeutic area
* Develop an understanding of the regional landscape including specialties involved in patient care
* Maintain effective and appropriate communication among internal stakeholders while maintaining full compliance with relevant requirements
* Generate tactical regional plans to provide needs‐based, value‐added support of the medical and scientific community in line with company goals
* Use systems to strategically map, identify, profile and prioritize thought leaders in line with the medical plan and goals
* Maintain accurate reporting and documentation of MSL activities
* Collaborate with internal cross‐functional stakeholders (e.g., Commercial, Market Access)
Education, Registration & Certification
* Tertiary qualification in health or medical science (MD, PhD, BPharm, BOptom, Borth, BSc); postgraduate studies highly desirable (e.g., Master's or PhD)
Experience
* At least 1‐3 years of experience in Medical Affairs or Medical Science with a high level of scientific and business acumen
* Comprehensive understanding of, and the ability to continue to learn and disseminate information about, the responsible disease area(s)
* Prior ophthalmology experience with knowledge of market dynamics in Australia (and New Zealand) and established relationships with eye care professionals is mandatory
* Understanding of compliance considerations and ability to work compliantly in a field‐based role, within the medical organization and across the commercial organization
* Thorough and current knowledge of the Medicines Australia Code of Conduct
Skills, Knowledge & Abilities
* Excellent oral and written communication skills
* Energetically embraces responsibilities and demonstrates the ability to achieve goals
* Strong initiative and functions well as part of a cross‐functional team
* Excellent time‐management and planning skills
* Ability to work independently and manage time effectively while traveling
* Proactive mindset with the ability to shape internal processes and contribute beyond the core job scope when opportunities arise
* Pro‐active team player, flexible, and able to work in a dynamic environment
Travel Requirements
* Regular travel within NSW and Queensland to engage with healthcare professionals and key stakeholders
* Occasional travel to national and international congresses and meetings may be required
* Must hold a valid driver's licence and have access to reliable transport for regional travel
Benefits and Perks
Apellis offers a comprehensive benefits package, inclusive flexible time off, summer and winter shutdowns, paid family leave and more!
Company Background
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company leading the way in complement science to develop life‐changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two C3‐targeting medicines approved to treat four serious diseases. Breakthroughs for patients include the first‐ever therapy for geographic atrophy, a leading cause of blindness, and the first treatment for patients 12 and older with C3G or primary IC‐MPGN, two severe, rare kidney diseases. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases.
For more information, please visit https://apellis.com or follow us on LinkedIn and X.
#J-18808-Ljbffr